Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer

Korean Journal of Internal Medicine

Volumn 29, Issue 6, 2014, Pages 830-833

  Lim, Jeong Uk ^a   Woo, In Sook ^a   Jung, Yun Hwa ^a   Byeon, Jae Ho ^a   Park, Chan Kwon ^a   Kim, Tae Jung ^a   Kim, Hyo Rim ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Acquired resistance; Erlotinib; Neuroendocrine

Indexed keywords

CD45 ANTIGEN; CHROMOGRANIN; CISPLATIN; CYTOKERATIN 20; CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; NAVELBINE; NEURON SPECIFIC ENOLASE; PEMETREXED; THYROID TRANSCRIPTION FACTOR 1; TOPOTECAN; VIMENTIN; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ADULT; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BRAIN METASTASIS; CANCER RESISTANCE; CANCER SIZE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; CYBERKNIFE; DIPLOPIA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEVER; GENE DELETION; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL NEUROENDOCRINE CARCINOMA; LETTER; LUNG ADENOCARCINOMA; LUNG NODULE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; STEREOTAXIC SURGERY; SUPERIOR CAVA VEIN SYNDROME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR LYSIS SYNDROME; ADENOCARCINOMA; BIOPSY; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; DRUG RESISTANCE; LARGE CELL CARCINOMA; LUNG NEOPLASMS; PATHOLOGY; SECONDARY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84908545787     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2014.29.6.830     Document Type: Letter

References (5)

1. Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013;31:1070-1080.
2. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
3. Zakowski MF, Ladanyi M, Kris MG; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006;355:213-215.
4. Popat S, Wotherspoon A, Nutting CM, Gonzalez D, Nicholson AG, O’Brien M. Transformation to “high grade” neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer 2013;80:1-4.
5. Yanagisawa S, Morikawa N, Kimura Y, Nagano Y, Murakami K, Tabata T. Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma. Respirology 2012;17:1275-1277.